AstraZeneca
AZN
419 hedge funds and large institutions have $7.42B invested in AstraZeneca in 2014 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 75 increasing their positions, 198 reducing their positions, and 57 closing their positions.
140% more funds holding in top 10
Funds holding in top 10: 5 → 12 (+7)
61% more call options, than puts
Call options by funds: $956M | Put options by funds: $595M
54% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 57
8% more funds holding
Funds holding: 388 → 419 (+31)
5% less capital invested
Capital invested by funds: $7.81B → $7.42B (-$387M)
1.63% less ownership
Funds ownership: 9.54% → 7.91% (-1.6%)
62% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 198
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$250M |
| 2 |
MCM
Mason Capital Management
New York
|
+$242M |
| 3 |
Jane Street
New York
|
+$132M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
+$117M |
| 5 |
OCAM
Owl Creek Asset Management
New York
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$621M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$484M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$276M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$210M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$189M |
AZN Hedge Fund Activity: Q2 2014 in Review
419 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2014, worth a combined $7.42B — down 5% from $7.81B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new AZN positions and 57 closed out — a net gain of 31 holders — while 75 added to existing stakes and 198 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $250M. The largest seller was Allianz Asset Management, cutting an estimated $621M.
- 419 institutional investors held AstraZeneca (AZN) as of Q2 2014, up from 388 in Q1 2014.
- Funds reported $7.42B of AstraZeneca stock for Q2 2014, down 5% quarter-over-quarter.
- 88 funds opened new AstraZeneca positions in Q2 2014 and 57 closed out, a net change of +31 holders.
- The largest AstraZeneca buyer in Q2 2014 was Franklin Resources, an estimated $250M added.
- The largest AstraZeneca seller in Q2 2014 was Allianz Asset Management, an estimated $621M sold.
Based on aggregated 13F filings for Q2 2014.